Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EBITDA (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed EBITDA for 8 consecutive years, with -$59.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 11.93% year-over-year to -$59.2 million, compared with a TTM value of -$250.9 million through Sep 2025, down 45.61%, and an annual FY2024 reading of -$167.6 million, up 8.09% over the prior year.
  • EBITDA was -$59.2 million for Q3 2025 at Bicycle Therapeutics, up from -$80.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$14.4 million in Q3 2021 and bottomed at -$80.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$38.3 million, with a median of -$39.4 million recorded in 2023.
  • The sharpest move saw EBITDA soared 33.88% in 2024, then plummeted 139.41% in 2025.
  • Year by year, EBITDA stood at -$18.2 million in 2021, then plummeted by 65.2% to -$30.1 million in 2022, then tumbled by 76.92% to -$53.3 million in 2023, then grew by 8.89% to -$48.6 million in 2024, then fell by 21.95% to -$59.2 million in 2025.
  • Business Quant data shows EBITDA for BCYC at -$59.2 million in Q3 2025, -$80.9 million in Q2 2025, and -$62.3 million in Q1 2025.